Found: 6
Select item for more details and to access through your institution.
Fasiglifam (TAK-875) has dual potentiating mechanisms via G αq-GPR40/FFAR1 signaling branches on glucose-dependent insulin secretion.
- Published in:
- Pharmacology Research & Perspectives, 2016, v. 4, n. 3, p. n/a, doi. 10.1002/prp2.237
- By:
- Publication type:
- Article
A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1.
- Published in:
- PLoS ONE, 2013, v. 8, n. 10, p. 1, doi. 10.1371/journal.pone.0076280
- By:
- Publication type:
- Article
The molecular weight ratio of monomethoxypolyethylene glycol (mPEG) to protein determines the immunotolerogenicity of mPEG proteins.
- Published in:
- Protein Engineering, 1999, v. 12, n. 8, p. 701, doi. 10.1093/protein/12.8.701
- By:
- Publication type:
- Article
GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve.
- Published in:
- PLoS ONE, 2019, v. 14, n. 9, p. 1, doi. 10.1371/journal.pone.0222653
- By:
- Publication type:
- Article
B-cell repertoire specific for an unfolded self-determinant of mouse lysozyme escape tolerance and dominantly participate in the autoantibody response.
- Published in:
- Immunology, 2002, v. 107, n. 4, p. 394, doi. 10.1046/j.1365-2567.2002.01528.x
- By:
- Publication type:
- Article
1161-P: SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control More Than That by Fasiglifam in Rat Models of Diabetes and Obesity.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1161-P
- By:
- Publication type:
- Article